These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 15033896)

  • 1. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias.
    Calon F; Dridi M; Hornykiewicz O; Bédard PJ; Rajput AH; Di Paolo T
    Brain; 2004 May; 127(Pt 5):1075-84. PubMed ID: 15033896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
    Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
    Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists.
    Pinna A; Wardas J; Simola N; Morelli M
    Life Sci; 2005 Nov; 77(26):3259-67. PubMed ID: 15979104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications.
    Morelli M; Di Paolo T; Wardas J; Calon F; Xiao D; Schwarzschild MA
    Prog Neurobiol; 2007 Dec; 83(5):293-309. PubMed ID: 17826884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
    Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias.
    Piccini P; Weeks RA; Brooks DJ
    Ann Neurol; 1997 Nov; 42(5):720-6. PubMed ID: 9392571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease.
    Kish SJ; Tong J; Hornykiewicz O; Rajput A; Chang LJ; Guttman M; Furukawa Y
    Brain; 2008 Jan; 131(Pt 1):120-31. PubMed ID: 17956909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats.
    Carta AR; Pinna A; Cauli O; Morelli M
    Synapse; 2002 Jun; 44(3):166-74. PubMed ID: 11954048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys.
    Chen L; Togasaki DM; Langston JW; Di Monte DA; Quik M
    Neuroscience; 2005; 132(2):409-20. PubMed ID: 15802193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias.
    Morgante F; Espay AJ; Gunraj C; Lang AE; Chen R
    Brain; 2006 Apr; 129(Pt 4):1059-69. PubMed ID: 16476674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain enkephalin receptors in Parkinson's disease.
    Rinne UK; Rinne JK; Rinne JO; Laakso K; Tenovuo O; Lönnberg P; Koskinen V
    J Neural Transm Suppl; 1983; 19():163-71. PubMed ID: 6321647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic interdependence of adenosine and dopamine receptors: evidence from receptor knockout mice.
    Short JL; Ledent C; Borrelli E; Drago J; Lawrence AJ
    Neuroscience; 2006 May; 139(2):661-70. PubMed ID: 16476524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental studies and theoretical aspects on A2A/D2 receptor interactions in a model of Parkinson's disease. Relevance for L-dopa induced dyskinesias.
    Antonelli T; Fuxe K; Agnati L; Mazzoni E; Tanganelli S; Tomasini MC; Ferraro L
    J Neurol Sci; 2006 Oct; 248(1-2):16-22. PubMed ID: 16765381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of A2A receptors plus l-DOPA after nigrostriatal lesion results in GAD67 mRNA changes different from l-DOPA alone in the rat globus pallidus and substantia nigra reticulata.
    Carta AR; Tabrizi MA; Baraldi PG; Pinna A; Pala P; Morelli M
    Exp Neurol; 2003 Dec; 184(2):679-87. PubMed ID: 14769359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution and modulation of histamine H(3) receptors in basal ganglia and frontal cortex of healthy controls and patients with Parkinson's disease.
    Anichtchik OV; Peitsaro N; Rinne JO; Kalimo H; Panula P
    Neurobiol Dis; 2001 Aug; 8(4):707-16. PubMed ID: 11493035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain receptor changes in Parkinson's disease in relation to the disease process and treatment.
    Rinne UK; Rinne JO; Rinne JK; Laakso K; Laihinen A; Lönnberg P
    J Neural Transm Suppl; 1983; 18():279-86. PubMed ID: 6308149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The treatment of Parkinson's disease--adenosine A2A receptor antagonists].
    Matsubara E; Shoji M; Abe K
    Nihon Rinsho; 2002 Jan; 60(1):112-6. PubMed ID: 11808320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenosine A(2A) receptors, dopamine D(2) receptors and their interactions in Parkinson's disease.
    Fuxe K; Marcellino D; Genedani S; Agnati L
    Mov Disord; 2007 Oct; 22(14):1990-2017. PubMed ID: 17618524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenosine A
    Waggan I; Rissanen E; Tuisku J; Joutsa J; Helin S; Parkkola R; Rinne JO; Airas L
    J Neurol; 2023 Jan; 270(1):300-310. PubMed ID: 36053386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenosine A2A-receptor antagonism and pathophysiology of Parkinson's disease and drug-induced movement disorders.
    Kulisevsky J; Poyurovsky M
    Eur Neurol; 2012; 67(1):4-11. PubMed ID: 22134373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.